nach oben

Inflammation

Erschienen in:

11.08.2022 | Review

NLRP3 Inflammasome in Atherosclerosis: Putting Out the Fire of Inflammation

verfasst von: Bo-Zong Shao, Hai-Yan Xu, Yi-Cheng Zhao, Xiao-Rui Zheng, Fang Wang, Guan-Ren Zhao

Erschienen in: Inflammation | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Atherosclerosis (AS) is a chronic inflammatory disease with thickening or hardening of the arteries, which led to the built-up of plaques in the inner lining of an artery. Among all the clarified pathogenesis, the over-activation of inflammatory reaction is one of the most acknowledged one. The nucleotide-binding domain leucine-rich repeat (NLR) and pyrin domain containing receptor 3 (NLRP3) inflammasome, as a vital and special form of inflammation and innate immunity, has been widely revealed to participate in the onset and development of AS. This review will introduce the process of the pathogenesis and progression of AS, and will describe the biological features of the NLRP3 inflammasome. Furthermore, the role of the NLRP3 inflammasome in AS and the possible mechanisms will be discussed. In addition, several kinds of agents with the effect of anti-atherosclerotic taking advantage of the NLRP3 inflammasome intervention will be described and discussed in detail, including natural compounds (baicalin, dihydromyricetin, luteolin, 5-deoxy-rutaecarpine (R3) and Salvianolic acid A, etc.), microRNAs (microRNA-30c-5p, microRNA-9, microRNA-146a-5p, microRNA-16-5p and microRNA-181a, etc.), and autophagy regulators (melatonin, dietary PUFA and arglabin, etc.). We aim to provide novel insights in the exploration of the specific mechanisms of AS and the development of new treatments of AS.

Manoogian, E.N.C., L.S. Chow, P.R. Taub, B. Laferrere, and S. Panda. 2022. Time-restricted Eating for the Prevention and Management of Metabolic Diseases. Endocrine Reviews 43 (2): 405–436. https://doi.org/10.1210/endrev/bnab027.CrossRefPubMed

Fahed, G., L. Aoun, M. Bou. Zerdan, S. Allam, M. Bou Zerdan, Y. Bouferraa, and H.I. Assi. 2022. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. International Journal of Molecular Sciences 23 (2). https://doi.org/10.3390/ijms23020786.

Colca, J.R., and P.E. Scherer. 2022. The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease. Molecular Metabolism 55: 101409. https://doi.org/10.1016/j.molmet.2021.101409.CrossRefPubMed

Valanti, E.K., K. Dalakoura-Karagkouni, G. Siasos, D. Kardassis, A.G. Eliopoulos, and D. Sanoudou. 2021. Advances in biological therapies for dyslipidemias and atherosclerosis. Metabolism 116: 154461. https://doi.org/10.1016/j.metabol.2020.154461.CrossRefPubMed

Atzeni, F., J. Rodriguez-Carrio, C.D. Popa, M.T. Nurmohamed, G. Szucs, and Z. Szekanecz. 2021. Cardiovascular effects of approved drugs for rheumatoid arthritis. Nature Reviews Rheumatology 17 (5): 270–290. https://doi.org/10.1038/s41584-021-00593-3.CrossRefPubMed

Jebari-Benslaiman, S., U. Galicia-Garcia, A. Larrea-Sebal, J.R. Olaetxea, I. Alloza, K. Vandenbroeck, A. Benito-Vicente, and C. Martin. 2022. Pathophysiology of Atherosclerosis. International Journal of Molecular Sciences 23 (6). https://doi.org/10.3390/ijms23063346.

Roy, P., M. Orecchioni, and K. Ley. 2022. How the immune system shapes atherosclerosis: Roles of innate and adaptive immunity. Nature Reviews Immunology 22 (4): 251–265. https://doi.org/10.1038/s41577-021-00584-1.CrossRefPubMed

Lin, L., M.X. Zhang, L. Zhang, D. Zhang, C. Li, and Y.L. Li. 2021. Autophagy, pyroptosis, and ferroptosis: New regulatory mechanisms for atherosclerosis. Frontiers in Cell and Developmental Biology 9: 809955. https://doi.org/10.3389/fcell.2021.809955.CrossRefPubMed

Fan, J., and T. Watanabe. 2022. Atherosclerosis: Known and unknown. Pathology International 72 (3): 151–160. https://doi.org/10.1111/pin.13202.CrossRefPubMed

10.

Libby, P. 2021. The changing landscape of atherosclerosis. Nature 592 (7855): 524–533. https://doi.org/10.1038/s41586-021-03392-8.CrossRefPubMed

11.

Geovanini, G.R., and P. Libby. 2018. Atherosclerosis and inflammation: Overview and updates. Clinical Science (London, England) 132 (12): 1243–1252. https://doi.org/10.1042/CS20180306.CrossRef

12.

Wolf, D., and K. Ley. 2019. Immunity and Inflammation in Atherosclerosis. Circulation Research 124 (2): 315–327. https://doi.org/10.1161/CIRCRESAHA.118.313591.CrossRefPubMedPubMedCentral

13.

Soehnlein, O., and P. Libby. 2021. Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nature Reviews. Drug Discovery 20 (8): 589–610. https://doi.org/10.1038/s41573-021-00198-1.CrossRefPubMedPubMedCentral

14.

Doran, A.C. 2022. Inflammation resolution: Implications for atherosclerosis. Circulation Research 130 (1): 130–148. https://doi.org/10.1161/CIRCRESAHA.121.319822.CrossRefPubMedPubMedCentral

15.

Kong, P., Z.Y. Cui, X.F. Huang, D.D. Zhang, R.J. Guo, and M. Han. 2022. Inflammation and atherosclerosis: Signaling pathways and therapeutic intervention. Signal Transduction and Targeted Therapy 7 (1): 131. https://doi.org/10.1038/s41392-022-00955-7.CrossRefPubMedPubMedCentral

16.

Ley, K. 2021. Inflammation and Atherosclerosis. Cells 10 (5). https://doi.org/10.3390/cells10051197.

17.

Yamada, S.M., and A. Pontillo. 2022. The genetics behind inflammasome regulation. Molecular Immunology 145: 27–42. https://doi.org/10.1016/j.molimm.2022.03.005.CrossRefPubMed

18.

Sharma, B.R., and T.D. Kanneganti. 2021. NLRP3 inflammasome in cancer and metabolic diseases. Nature Immunology 22 (5): 550–559. https://doi.org/10.1038/s41590-021-00886-5.CrossRefPubMedPubMedCentral

19.

Pandey, A., C. Shen, S. Feng, and S.M. Man. 2021. Cell biology of inflammasome activation. Trends in Cell Biology 31 (11): 924–939. https://doi.org/10.1016/j.tcb.2021.06.010.CrossRefPubMed

20.

Kelley, N., D. Jeltema, Y. Duan, and Y. He. 2019. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. International Journal of Molecular Sciences 20 (13). https://doi.org/10.3390/ijms20133328.

21.

Qiu, Y., Y. Huang, M. Chen, Y. Yang, X. Li, and W. Zhang. 2022. Mitochondrial DNA in NLRP3 inflammasome activation. International Immunopharmacology 108: 108719. https://doi.org/10.1016/j.intimp.2022.108719.CrossRefPubMed

22.

Kong, R., L. Sun, H. Li, and D. Wang. 2022. The role of NLRP3 inflammasome in the pathogenesis of rheumatic disease. Autoimmunity 55 (1): 1–7. https://doi.org/10.1080/08916934.2021.1995860.CrossRefPubMed

23.

Paget, C., E. Doz-Deblauwe, N. Winter, and B. Briard. 2022. Specific NLRP3 inflammasome assembling and regulation in neutrophils: relevance in inflammatory and infectious diseases. Cells 11 (7). https://doi.org/10.3390/cells11071188.

24.

Hochheiser, M., IV., G Hagelueken Pilsl, J. Moecking, M. Marleaux, R. Brinkschulte, E. Latz, C. Engel, and M. Geyer. 2022. Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. Nature 604 (7904): 184–189. https://doi.org/10.1038/s41586-022-04467-w.CrossRefPubMed

25.

Thompson, R.C., A.H. Allam, G.P. Lombardi, L.S. Wann, M.L. Sutherland, J.D. Sutherland, M.A. Soliman, et al. 2013. Atherosclerosis across 4000 years of human history: The Horus study of four ancient populations. Lancet 381 (9873): 1211–1222. https://doi.org/10.1016/S0140-6736(13)60598-X.CrossRefPubMed

26.

Chu, C.S., S.H. Law, D. Lenzen, Y.H. Tan, S.F. Weng, E. Ito, J.C. Wu, C.H. Chen, H.C. Chan, and L.Y. Ke. 2020. Clinical significance of electronegative low-density lipoprotein cholesterol in atherothrombosis. Biomedicines 8 (8). https://doi.org/10.3390/biomedicines8080254.

27.

Dutta, P., G. Courties, Y. Wei, F. Leuschner, R. Gorbatov, C.S. Robbins, Y. Iwamoto, et al. 2012. Myocardial infarction accelerates atherosclerosis. Nature 487 (7407): 325–329. https://doi.org/10.1038/nature11260.CrossRefPubMedPubMedCentral

28.

Palasubramaniam, J., X. Wang, and K. Peter. 2019. Myocardial infarction-from atherosclerosis to thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology 39 (8): e176–e185. https://doi.org/10.1161/ATVBAHA.119.312578.CrossRefPubMed

29.

Porsch, F., Z. Mallat, and C.J. Binder. 2021. Humoral immunity in atherosclerosis and myocardial infarction: From B cells to antibodies. Cardiovascular Research 117 (13): 2544–2562. https://doi.org/10.1093/cvr/cvab285.CrossRefPubMed

30.

Chandrasekar, B., and M. Alanbaei. 2020. Intracoronary imaging identifies plaque rupture underlying left main thrombosis in acute myocardial infarction without angiographically evident atherosclerosis. European Heart Journal 41 (46): 4448. https://doi.org/10.1093/eurheartj/ehaa849.CrossRefPubMed

31.

Tedeschi, D., A. Rizzi, S. Biscaglia, and C. Tumscitz. 2021. Acute myocardial infarction and large coronary thrombosis in a patient with COVID-19. Catheterization and Cardiovascular Interventions 97 (2): 272–277. https://doi.org/10.1002/ccd.29179.CrossRefPubMed

32.

Loczi, L., J. Kappelmayer, T. Tarr, and Z. Bagoly. 2020. Antiphospholipid syndrome and the risk of myocardial infarction: Current evidence and uncertainties. Kardiologia Polska 78 (1): 6–14. https://doi.org/10.33963/KP.15090.CrossRefPubMed

33.

Shao, B.Z., B.Z. Han, Y.X. Zeng, D.F. Su, and C. Liu. 2016. The roles of macrophage autophagy in atherosclerosis. Acta Pharmacologica Sinica 37 (2): 150–156. https://doi.org/10.1038/aps.2015.87.CrossRefPubMedPubMedCentral

34.

Emini Veseli, B., P. Perrotta, G.R.A. De Meyer, L. Roth, C. Van der Donckt, W. Martinet, and G.R.Y. De Meyer. 2017. Animal models of atherosclerosis. European Journal of Pharmacology 816: 3–13. https://doi.org/10.1016/j.ejphar.2017.05.010.CrossRefPubMed

35.

Miao, J., X. Zang, X. Cui, and J. Zhang. 2020. Autophagy, Hyperlipidemia, and Atherosclerosis. Advances in Experimental Medicine and Biology 1207: 237–264. https://doi.org/10.1007/978-981-15-4272-5_18.CrossRefPubMed

36.

Fredman, G. 2020. Devouring atherosclerotic plaques. Nature Nanotechnology 15 (2): 84–85. https://doi.org/10.1038/s41565-019-0599-3.CrossRefPubMed

37.

Jinnouchi, H., Y. Sato, A. Sakamoto, A. Cornelissen, M. Mori, R. Kawakami, N.V. Gadhoke, F.D. Kolodgie, R. Virmani, and A.V. Finn. 2020. Calcium deposition within coronary atherosclerotic lesion: Implications for plaque stability. Atherosclerosis 306: 85–95. https://doi.org/10.1016/j.atherosclerosis.2020.05.017.CrossRefPubMed

38.

Munjal, A., and R. Khandia. 2020. Atherosclerosis: Orchestrating cells and biomolecules involved in its activation and inhibition. Advances in Protein Chemistry and Structural Biology 120: 85–122. https://doi.org/10.1016/bs.apcsb.2019.11.002.CrossRefPubMed

39.

Linton, M.R.F., P.G. Yancey, S.S. Davies, W.G. Jerome, E.F. Linton, W.L. Song, A.C. Doran, and K.C. Vickers. 2000. The Role of Lipids and Lipoproteins in Atherosclerosis. In Endotext, eds. K. R. Feingold, and B. Anawalt, and A. Boyce, and G. Chrousos, and W. W. de Herder, and K. Dhatariya, and K. Dungan et al. South Dartmouth (MA).

40.

Li, J., Q. Meng, Y. Fu, X. Yu, T. Ji, Y. Chao, Q. Chen, Y. Li, and H. Bian. 2021. Novel insights: Dynamic foam cells derived from the macrophage in atherosclerosis. Journal of Cellular Physiology 236 (9): 6154–6167. https://doi.org/10.1002/jcp.30300.CrossRefPubMed

41.

Tabas, I., and K.E. Bornfeldt. 2016. Macrophage phenotype and function in different stages of atherosclerosis. Circulation Research 118 (4): 653–667. https://doi.org/10.1161/CIRCRESAHA.115.306256.CrossRefPubMedPubMedCentral

42.

Maguire, E.M., S.W.A. Pearce, and Q. Xiao. 2019. Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease. Vascular Pharmacology 112: 54–71. https://doi.org/10.1016/j.vph.2018.08.002.CrossRefPubMed

43.

Sturtzel, C. 2017. Endothelial Cells. Advances in Experimental Medicine and Biology 1003: 71–91. https://doi.org/10.1007/978-3-319-57613-8_4.CrossRefPubMed

44.

Liang, H., R. Yue, C. Zhou, M. Liu, X. Yu, S. Lu, J. Zeng, Z. Yu, Z. Zhou, and H. Hu. 2021. Cadmium exposure induces endothelial dysfunction via disturbing lipid metabolism in human microvascular endothelial cells. Journal of Applied Toxicology 41 (5): 775–788. https://doi.org/10.1002/jat.4115.CrossRefPubMed

45.

Ding, Y., Y. Feng, W. Zhu, Y. Zou, Y. Xie, F. Wang, C.F. Liu, Y. Zhang, and H. Liu. 2019. [Gly14]-Humanin prevents lipid deposition and endothelial cell apoptosis in a lectin-like oxidized low-density lipoprotein receptor-1-dependent manner. Lipids 54 (11–12): 697–705. https://doi.org/10.1002/lipd.12195.CrossRefPubMed

46.

Yang, S., H.Q. Yuan, Y.M. Hao, Z. Ren, S.L. Qu, L.S. Liu, D.H. Wei, Z.H. Tang, J.F. Zhang, and Z.S. Jiang. 2020. Macrophage polarization in atherosclerosis. Clinica Chimica Acta 501: 142–146. https://doi.org/10.1016/j.cca.2019.10.034.CrossRef

47.

Wculek, S.K., G. Dunphy, I. Heras-Murillo, A. Mastrangelo, and D. Sancho. 2022. Metabolism of tissue macrophages in homeostasis and pathology. Cellular & Molecular Immunology 19 (3): 384–408. https://doi.org/10.1038/s41423-021-00791-9.CrossRef

48.

Zhang, X., J.G. McDonald, B. Aryal, A. Canfran-Duque, E.L. Goldberg, E. Araldi, W. Ding, et al. 2021. Desmosterol suppresses macrophage inflammasome activation and protects against vascular inflammation and atherosclerosis. Proceedings of the National Academy of Sciences USA 118 (47). https://doi.org/10.1073/pnas.2107682118.

49.

Sergin, I., T.D. Evans, X. Zhang, S. Bhattacharya, C.J. Stokes, E. Song, S. Ali, et al. 2017. Exploiting macrophage autophagy-lysosomal biogenesis as a therapy for atherosclerosis. Nature Communications 8: 15750. https://doi.org/10.1038/ncomms15750.CrossRefPubMedPubMedCentral

50.

Li, X., R. Zhu, H. Jiang, Q. Yin, J. Gu, J. Chen, X. Ji, et al. 2022. Autophagy enhanced by curcumin ameliorates inflammation in atherogenesis via the TFEB-P300-BRD4 axis. Acta Pharm Sin B 12 (5): 2280–2299. https://doi.org/10.1016/j.apsb.2021.12.014.CrossRefPubMed

51.

Libby, P. 2021. Inflammation in atherosclerosis-no longer a theory. Clinical Chemistry 67 (1): 131–142. https://doi.org/10.1093/clinchem/hvaa275.CrossRefPubMed

52.

Tissot, A.C., G. Spohn, G.T. Jennings, A. Shamshiev, M.O. Kurrer, R. Windak, M. Meier, et al. 2013. A VLP-based vaccine against interleukin-1alpha protects mice from atherosclerosis. European Journal of Immunology 43 (3): 716–722. https://doi.org/10.1002/eji.201242687.CrossRefPubMed

53.

Xu, F., J. Zhang, X. Zhou, and H. Hao. 2022. Lipoxin A4 and its analog attenuate high fat diet-induced atherosclerosis via Keap1/Nrf2 pathway. Experimental Cell Research 412 (1): 113025. https://doi.org/10.1016/j.yexcr.2022.113025.CrossRefPubMed

54.

Pieczynska, M.D., Y. Yang, S. Petrykowski, O.K. Horbanczuk, A.G. Atanasov, and J.O. Horbanczuk. 2020. Gut microbiota and its metabolites in atherosclerosis development. Molecules 25 (3). https://doi.org/10.3390/molecules25030594.

55.

Yang, H., H. Li, W. Chen, Z. Mei, Y. Yuan, X. Wang, L. Chu, et al. 2021. Therapeutic effect of Schistosoma japonicum cystatin on atherosclerotic renal damage. Frontiers in Cell and Developmental Biology 9: 760980. https://doi.org/10.3389/fcell.2021.760980.CrossRefPubMedPubMedCentral

56.

Ma, J., D. Zhao, X. Wang, C. Ma, K. Feng, S. Zhang, Y. Chen, et al. 2019. LongShengZhi Capsule reduces established atherosclerotic lesions in apoE-deficient mice by ameliorating hepatic lipid metabolism and inhibiting inflammation. Journal of Cardiovascular Pharmacology 73 (2): 105–117. https://doi.org/10.1097/FJC.0000000000000642.CrossRefPubMed

57.

Edsfeldt, A., M. Swart, P. Singh, L. Dib, J. Sun, J.E. Cole, I. Park, et al. 2022. Interferon regulatory factor-5-dependent CD11c+ macrophages contribute to the formation of rupture-prone atherosclerotic plaques. European Heart Journal 43 (19): 1864–1877. https://doi.org/10.1093/eurheartj/ehab920.CrossRefPubMedPubMedCentral

58.

Li, H., Z. Cao, L. Wang, C. Liu, H. Lin, Y. Tang, and P. Yao. 2022. Macrophage subsets and death are responsible for atherosclerotic plaque formation. Frontiers in Immunology 13: 843712. https://doi.org/10.3389/fimmu.2022.843712.CrossRefPubMedPubMedCentral

59.

Huang, S.U., and K.M. O'Sullivan. 2022. The expanding role of extracellular traps in inflammation and autoimmunity: the new players in casting dark webs. International Journal of Molecular Sciences 23 (7). https://doi.org/10.3390/ijms23073793.

60.

Francis, G.A., and B. Razani. 2022. Autophagy in atherosclerosis: Not all foam cells are created equal. Circulation Research 130 (6): 848–850. https://doi.org/10.1161/CIRCRESAHA.122.320857.CrossRefPubMed

61.

Qiao, L., J. Ma, Z. Zhang, W. Sui, C. Zhai, D. Xu, Z. Wang, et al. 2021. Deficient chaperone-mediated autophagy promotes inflammation and atherosclerosis. Circulation Research 129 (12): 1141–1157. https://doi.org/10.1161/CIRCRESAHA.121.318908.CrossRefPubMedPubMedCentral

62.

Barrett, T.J. 2020. Macrophages in atherosclerosis regression. Arteriosclerosis, Thrombosis, and Vascular Biology 40 (1): 20–33. https://doi.org/10.1161/ATVBAHA.119.312802.CrossRefPubMed

63.

Chistiakov, D.A., V.A. Myasoedova, V.V. Revin, A.N. Orekhov, and Y.V. Bobryshev. 2018. The impact of interferon-regulatory factors to macrophage differentiation and polarization into M1 and M2. Immunobiology 223 (1): 101–111. https://doi.org/10.1016/j.imbio.2017.10.005.CrossRefPubMed

64.

Silvis, M.J.M., E.J. Demkes, A.T.L. Fiolet, M. Dekker, L. Bosch, G.P.J. van Hout, L. Timmers, and D.P.V. de Kleijn. 2021. Immunomodulation of the NLRP3 inflammasome in atherosclerosis, coronary artery disease, and acute myocardial infarction. Journal of Cardiovascular Translational Research 14 (1): 23–34. https://doi.org/10.1007/s12265-020-10049-w.CrossRefPubMed

65.

Abbate, A., S. Toldo, C. Marchetti, J. Kron, B.W. Van Tassell, and C.A. Dinarello. 2020. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Circulation Research 126 (9): 1260–1280. https://doi.org/10.1161/CIRCRESAHA.120.315937.CrossRefPubMedPubMedCentral

66.

He, X., X. Fan, B. Bai, N. Lu, S. Zhang, and L. Zhang. 2021. Pyroptosis is a critical immune-inflammatory response involved in atherosclerosis. Pharmacological Research 165: 105447. https://doi.org/10.1016/j.phrs.2021.105447.CrossRefPubMed

67.

Kaur, B.P., and E. Secord. 2021. Innate Immunity. Immunology and Allergy Clinics of North America 41 (4): 535–541. https://doi.org/10.1016/j.iac.2021.07.003.CrossRefPubMed

68.

Taguchi, T., and K. Mukai. 2019. Innate immunity signalling and membrane trafficking. Current Opinion in Cell Biology 59: 1–7. https://doi.org/10.1016/j.ceb.2019.02.002.CrossRefPubMed

69.

Sokol, C.L., and A.D. Luster. 2015. The chemokine system in innate immunity. Cold Spring Harbor Perspectives in Biology 7 (5). https://doi.org/10.1101/cshperspect.a016303.

70.

Zhang, Q., and X. Cao. 2021. Epigenetic remodeling in innate immunity and inflammation. Annual Review of Immunology 39: 279–311. https://doi.org/10.1146/annurev-immunol-093019-123619.CrossRefPubMed

71.

Ratajczak, M.Z., and J. Ratajczak. 2021. Innate Immunity Communicates Using the Language of Extracellular Microvesicles. Stem Cell Reviews and Reports 17 (2): 502–510. https://doi.org/10.1007/s12015-021-10138-6.CrossRefPubMedPubMedCentral

72.

Yan, Z., Z. Qi, X. Yang, N. Ji, Y. Wang, Q. Shi, M. Li, J. Zhang, and Y. Zhu. 2021. The NLRP3 inflammasome: Multiple activation pathways and its role in primary cells during ventricular remodeling. Journal of Cellular Physiology 236 (8): 5547–5563. https://doi.org/10.1002/jcp.30285.CrossRefPubMed

73.

Fann, D.Y., S.Y. Lee, S. Manzanero, P. Chunduri, C.G. Sobey, and T.V. Arumugam. 2013. Pathogenesis of acute stroke and the role of inflammasomes. Ageing Research Reviews 12 (4): 941–966. https://doi.org/10.1016/j.arr.2013.09.004.CrossRefPubMed

74.

Huang, Y., W. Xu, and R. Zhou. 2021. NLRP3 inflammasome activation and cell death. Cellular & Molecular Immunology 18 (9): 2114–2127. https://doi.org/10.1038/s41423-021-00740-6.CrossRef

75.

Paik, S., J.K. Kim, P. Silwal, C. Sasakawa, and E.K. Jo. 2021. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cellular & Molecular Immunology 18 (5): 1141–1160. https://doi.org/10.1038/s41423-021-00670-3.CrossRef

76.

Mezzaroma, E., A. Abbate, and S. Toldo. 2021. NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases. Molecules 26 (4). https://doi.org/10.3390/molecules26040976.

77.

Liu, B., and J. Yu. 2021. Anti-NLRP3 Inflammasome Natural Compounds: An Update. Biomedicines 9 (2). https://doi.org/10.3390/biomedicines9020136.

78.

Toldo, S., E. Mezzaroma, L.F. Buckley, N. Potere, M. Di Nisio, G. Biondi-Zoccai, B.W. Van Tassell, and A. Abbate. 2021. Targeting the NLRP3 inflammasome in cardiovascular diseases. Pharmacology & Therapeutics 236: 108053. https://doi.org/10.1016/j.pharmthera.2021.108053.CrossRef

79.

Shao, B.Z., Z.Q. Xu, B.Z. Han, D.F. Su, and C. Liu. 2015. NLRP3 inflammasome and its inhibitors: A review. Frontiers in Pharmacology 6: 262. https://doi.org/10.3389/fphar.2015.00262.CrossRefPubMedPubMedCentral

80.

Zahid, A., B. Li, A.J.K. Kombe, T. Jin, and J. Tao. 2019. Pharmacological Inhibitors of the NLRP3 Inflammasome. Frontiers in Immunology 10: 2538. https://doi.org/10.3389/fimmu.2019.02538.CrossRefPubMedPubMedCentral

81.

Seoane, P.I., B. Lee, C. Hoyle, S. Yu, G. Lopez-Castejon, M. Lowe, and D. Brough. 2020. The NLRP3-inflammasome as a sensor of organelle dysfunction. Journal of Cell Biology 219 (12). https://doi.org/10.1083/jcb.202006194.

82.

Yang, Y., H. Wang, M. Kouadir, H. Song, and F. Shi. 2019. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death & Disease 10 (2): 128. https://doi.org/10.1038/s41419-019-1413-8.CrossRef

83.

Zhao, C., and W. Zhao. 2020. NLRP3 Inflammasome-A Key Player in Antiviral Responses. Frontiers in Immunology 11: 211. https://doi.org/10.3389/fimmu.2020.00211.CrossRefPubMedPubMedCentral

84.

Jo, E.K., J.K. Kim, D.M. Shin, and C. Sasakawa. 2016. Molecular mechanisms regulating NLRP3 inflammasome activation. Cellular & Molecular Immunology 13 (2): 148–159. https://doi.org/10.1038/cmi.2015.95.CrossRef

85.

El-Sharkawy, L.Y., D. Brough, and S. Freeman. 2020. Inhibiting the NLRP3 Inflammasome. Molecules 25 (23). https://doi.org/10.3390/molecules25235533.

86.

Wang, L., and A.V. Hauenstein. 2020. The NLRP3 inflammasome: Mechanism of action, role in disease and therapies. Molecular Aspects of Medicine 76: 100889. https://doi.org/10.1016/j.mam.2020.100889.CrossRefPubMed

87.

Hamarsheh, S., and R. Zeiser. 2020. NLRP3 inflammasome activation in cancer: A double-edged sword. Frontiers in Immunology 11: 1444. https://doi.org/10.3389/fimmu.2020.01444.CrossRefPubMedPubMedCentral

88.

Walsh, GM. 2009. Canakinumab for the treatment of cryopyrin-associated periodic syndromes. Drugs Today (Barc) 45 (10):731-735. https://doi.org/1396674/dot.2009.45.10.1416583

89.

Church, L.D., and M.F. McDermott. 2010. Canakinumab: A human anti-IL-1beta monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes. Expert Review of Clinical Immunology 6 (6): 831–841. https://doi.org/10.1586/eci.10.66.CrossRefPubMed

90.

Kuemmerle-Deschner, J.B. 2015. CAPS–pathogenesis, presentation and treatment of an autoinflammatory disease. Semin Immunopathol 37 (4): 377–385. https://doi.org/10.1007/s00281-015-0491-7.CrossRefPubMed

91.

Nakanishi, H., P. Prakash, T. Ito, H.J. Kim, C.C. Brewer, D. Harrow, I. Roux, S. Hosokawa, and A.J. Griffith. 2020. Genetic hearing loss associated with autoinflammation. Frontiers in Neurology 11: 141. https://doi.org/10.3389/fneur.2020.00141.CrossRefPubMedPubMedCentral

92.

Ferrucci, L., and E. Fabbri. 2018. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nature Reviews. Cardiology 15 (9): 505–522. https://doi.org/10.1038/s41569-018-0064-2.CrossRefPubMedPubMedCentral

93.

Ridker, P.M., T. Thuren, A. Zalewski, and P. Libby. 2011. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). American Heart Journal 162 (4): 597–605. https://doi.org/10.1016/j.ahj.2011.06.012.CrossRefPubMed

94.

Zhang, Y., X. Li, A.L. Pitzer, Y. Chen, L. Wang, and P.L. Li. 2015. Coronary endothelial dysfunction induced by nucleotide oligomerization domain-like receptor protein with pyrin domain containing 3 inflammasome activation during hypercholesterolemia: Beyond inflammation. Antioxidants & Redox Signaling 22 (13): 1084–1096. https://doi.org/10.1089/ars.2014.5978.CrossRef

95.

Freigang, S., F. Ampenberger, G. Spohn, S. Heer, A.T. Shamshiev, J. Kisielow, M. Hersberger, M. Yamamoto, M.F. Bachmann, and M. Kopf. 2011. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. European Journal of Immunology 41 (7): 2040–2051. https://doi.org/10.1002/eji.201041316.CrossRefPubMed

96.

Rajamaki, K., J. Lappalainen, K. Oorni, E. Valimaki, S. Matikainen, P.T. Kovanen, and K.K. Eklund. 2010. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation. PLoS ONE 5 (7): e11765. https://doi.org/10.1371/journal.pone.0011765.CrossRefPubMedPubMedCentral

97.

Hoseini, Z., F. Sepahvand, B. Rashidi, A. Sahebkar, A. Masoudifar, and H. Mirzaei. 2018. NLRP3 inflammasome: Its regulation and involvement in atherosclerosis. Journal of Cellular Physiology 233 (3): 2116–2132. https://doi.org/10.1002/jcp.25930.CrossRefPubMed

98.

Karasawa, T., and M. Takahashi. 2017. Role of NLRP3 Inflammasomes in Atherosclerosis. Journal of Atherosclerosis and Thrombosis 24 (5): 443–451. https://doi.org/10.5551/jat.RV17001.CrossRefPubMedPubMedCentral

99.

Kimura, Y., T. Yanagida, A. Onda, D. Tsukui, M. Hosoyamada, and H. Kono. 2020. Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology 40 (3): 570–582. https://doi.org/10.1161/ATVBAHA.119.313224.CrossRefPubMed

100.

Xing, S.S., J. Yang, W.J. Li, J. Li, L. Chen, Y.T. Yang, X. Lei, J. Li, K. Wang, and X. Liu. 2020. Salidroside decreases atherosclerosis plaque formation via inhibiting endothelial cell pyroptosis. Inflammation 43 (2): 433–440. https://doi.org/10.1007/s10753-019-01106-x.CrossRefPubMed

101.

Jin, H., Y. Zhu, X.D. Wang, E.F. Luo, Y.P. Li, B.L. Wang, and Y.F. Chen. 2021. BDNF corrects NLRP3 inflammasome-induced pyroptosis and glucose metabolism reprogramming through KLF2/HK1 pathway in vascular endothelial cells. Cellular Signalling 78: 109843. https://doi.org/10.1016/j.cellsig.2020.109843.CrossRefPubMed

102.

Li, W.L., L.G. Hua, P. Qu, W.H. Yan, C. Ming, Y.D. Jun, L.D. Yuan, and N. Nan. 2016. NLRP3 inflammasome: A novel link between lipoproteins and atherosclerosis. Archives of Medical Science 12 (5): 950–958. https://doi.org/10.5114/aoms.2016.61356.CrossRefPubMedPubMedCentral

103.

Zeng, Z., Q. Zheng, J. Chen, X. Tan, Q. Li, L. Ding, R. Zhang, and X. Lin. 2020. FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis. Experimental Cell Research 393 (2): 112108. https://doi.org/10.1016/j.yexcr.2020.112108.CrossRefPubMed

104.

Dintcheva, N.T., G. Infurna, M. Baiamonte, and F. D'Anna. 2020. Natural compounds as sustainable additives for biopolymers. Polymers (Basel) 12 (4). https://doi.org/10.3390/polym12040732.

105.

Woodbury, A., M.R. McCrary, and S.P. Yu. 2018. Molecular targets and natural compounds in drug development for the treatment of inflammatory pain. Current Drug Targets 19 (16): 1905–1915. https://doi.org/10.2174/1389450119666180514120438.CrossRefPubMed

106.

Zhang, S., R. Zhong, S. Tang, H. Han, L. Chen, and H. Zhang. 2022. Baicalin alleviates short-term lincomycin-induced intestinal and liver injury and inflammation in infant mice. International Journal of Molecular Sciences 23 (11). https://doi.org/10.3390/ijms23116072.

107.

Hu, Z., Y. Guan, W. Hu, Z. Xu, and M. Ishfaq. 2022. An overview of pharmacological activities of baicalin and its aglycone baicalein: New insights into molecular mechanisms and signaling pathways. Iranian Journal of Basic Medical Sciences 25 (1): 14–26. https://doi.org/10.22038/IJBMS.2022.60380.13381.CrossRefPubMedPubMedCentral

108.

Zhao, J., Z. Wang, Z. Yuan, S. Lv, and Q. Su. 2020. Baicalin ameliorates atherosclerosis by inhibiting NLRP3 inflammasome in apolipoprotein E-deficient mice. Diabetes & Vascular Disease Research 17 (6): 1479164120977441. https://doi.org/10.1177/1479164120977441.CrossRef

109.

Sun, Y., S. Liu, S. Yang, C. Chen, Y. Yang, M. Lin, C. Liu, et al. 2021. Mechanism of dihydromyricetin on inflammatory diseases. Frontiers in Pharmacology 12: 794563. https://doi.org/10.3389/fphar.2021.794563.CrossRefPubMed

110.

Wang, Y., J. Wang, H. Xiang, P. Ding, T. Wu, and G. Ji. 2022. Recent update on application of dihydromyricetin in metabolic related diseases. Biomedicine & Pharmacotherapy 148: 112771. https://doi.org/10.1016/j.biopha.2022.112771.CrossRef

111.

Hu, Q., T. Zhang, L. Yi, X. Zhou, and M. Mi. 2018. Dihydromyricetin inhibits NLRP3 inflammasome-dependent pyroptosis by activating the Nrf2 signaling pathway in vascular endothelial cells. BioFactors 44 (2): 123–136. https://doi.org/10.1002/biof.1395.CrossRefPubMed

112.

Ge, X., X. He, J. Liu, F. Zeng, L. Chen, W. Xu, R. Shao, et al. 2022. Amelioration of type 2 diabetes by the novel 6, 8-guanidyl luteolin quinone-chromium coordination via biochemical mechanisms and gut microbiota interaction. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2022.06.003.CrossRefPubMed

113.

Wang, H., X. Yao, K. Huang, J. Zhang, J. Xiao, J. Guo, D. Wei, and B. Xiang. 2022. Low-dose dexamethasone in combination with luteolin improves myocardial infarction recovery by activating the antioxidative response. Biomedicine & Pharmacotherapy 151: 113121. https://doi.org/10.1016/j.biopha.2022.113121.CrossRef

114.

Zhang, B.C., Z. Li, W. Xu, C.H. Xiang, and Y.F. Ma. 2018. Luteolin alleviates NLRP3 inflammasome activation and directs macrophage polarization in lipopolysaccharide-stimulated RAW264.7 cells. American Journal of Translational Research 10 (1):265–273.

115.

Luo, J., X. Wang, X. Jiang, C. Liu, Y. Li, X. Han, X. Zuo, et al. 2020. Rutaecarpine derivative R3 attenuates atherosclerosis via inhibiting NLRP3 inflammasome-related inflammation and modulating cholesterol transport. The FASEB Journal 34 (1): 1398–1411. https://doi.org/10.1096/fj.201900903RRR.CrossRefPubMed

116.

Zhou, F., L. Yao, X. Lu, Y. Li, X. Han, and P. Wang. 2022. Therapeutic targeting of GSK3beta-regulated Nrf2 and NFkappaB signaling pathways by salvianolic acid a ameliorates peritoneal fibrosis. Front Med (Lausanne) 9: 804899. https://doi.org/10.3389/fmed.2022.804899.CrossRefPubMed

117.

Li, S., R. Wang, F. Song, P. Chen, Y. Gu, C. Chen, and Y. Yuan. 2022. Salvianolic acid A suppresses CCl4-induced liver fibrosis through regulating the Nrf2/HO-1, NF-kappaB/IkappaBalpha, p38 MAPK, and JAK1/STAT3 signaling pathways. Drug and Chemical Toxicology pp 1–10. https://doi.org/10.1080/01480545.2022.2028822.

118.

Ma, Q., Q. Yang, J. Chen, C. Yu, L. Zhang, W. Zhou, and M. Chen. 2020. Salvianolic acid a ameliorates early-stage atherosclerosis development by inhibiting NLRP3 inflammasome activation in Zucker diabetic fatty rats. Molecules 25 (5). https://doi.org/10.3390/molecules25051089.

119.

Mohr, A.M., and J.L. Mott. 2015. Overview of microRNA biology. Seminars in Liver Disease 35 (1): 3–11. https://doi.org/10.1055/s-0034-1397344.CrossRefPubMedPubMedCentral

120.

Lu, T.X., and M.E. Rothenberg. 2018. MicroRNA. The Journal of Allergy and Clinical Immunology 141 (4): 1202–1207. https://doi.org/10.1016/j.jaci.2017.08.034.CrossRefPubMed

121.

Xu, B., Y.Y. Li, J. Ma, and F.X. Pei. 2016. Roles of microRNA and signaling pathway in osteoarthritis pathogenesis. Journal of Zhejiang University. Science. B 17 (3): 200–208. https://doi.org/10.1631/jzus.B1500267.CrossRefPubMedPubMedCentral

122.

Tian, T., J. Wang, and X. Zhou. 2015. A review: MicroRNA detection methods. Organic & Biomolecular Chemistry 13 (8): 2226–2238. https://doi.org/10.1039/c4ob02104e.CrossRef

123.

Li, P., X. Zhong, J. Li, H. Liu, X. Ma, R. He, and Y. Zhao. 2018. MicroRNA-30c-5p inhibits NLRP3 inflammasome-mediated endothelial cell pyroptosis through FOXO3 down-regulation in atherosclerosis. Biochemical and Biophysical Research Communications 503 (4): 2833–2840. https://doi.org/10.1016/j.bbrc.2018.08.049.CrossRefPubMed

124.

Wang, Y., Z. Han, Y. Fan, J. Zhang, K. Chen, L. Gao, H. Zeng, J. Cao, and C. Wang. 2017. MicroRNA-9 Inhibits NLRP3 Inflammasome Activation in Human Atherosclerosis Inflammation Cell Models through the JAK1/STAT Signaling Pathway. Cellular Physiology and Biochemistry 41 (4): 1555–1571. https://doi.org/10.1159/000470822.CrossRefPubMed

125.

Hou, J., Q. Deng, X. Deng, W. Zhong, S. Liu, and Z. Zhong. 2021. MicroRNA-146a-5p alleviates lipopolysaccharide-induced NLRP3 inflammasome injury and pro-inflammatory cytokine production via the regulation of TRAF6 and IRAK1 in human umbilical vein endothelial cells (HUVECs). Annals of Translational Medicine 9 (18): 1433. https://doi.org/10.21037/atm-21-3903.CrossRefPubMedPubMedCentral

126.

Li, B., Z. Zhang, and Y. Fu. 2021. Anti-inflammatory effects of artesunate on atherosclerosis via miR-16-5p and TXNIP regulation of the NLRP3 inflammasome. Annals of Translational Medicine 9 (20): 1558. https://doi.org/10.21037/atm-21-4939.CrossRefPubMedPubMedCentral

127.

Song, J., S. Yang, R. Yin, Q. Xiao, A. Ma, and X. Pan. 2019. MicroRNA-181a regulates the activation of the NLRP3 inflammatory pathway by targeting MEK1 in THP-1 macrophages stimulated by ox-LDL. Journal of Cellular Biochemistry 120 (8): 13640–13650. https://doi.org/10.1002/jcb.28637.CrossRefPubMed

128.

Glick, D., S. Barth, and K.F. Macleod. 2010. Autophagy: Cellular and molecular mechanisms. The Journal of Pathology 221 (1): 3–12. https://doi.org/10.1002/path.2697.CrossRefPubMed

129.

Levine, B., and G. Kroemer. 2019. Biological Functions of Autophagy Genes: A Disease Perspective. Cell 176 (1–2): 11–42. https://doi.org/10.1016/j.cell.2018.09.048.CrossRefPubMedPubMedCentral

130.

Klionsky, D.J., G. Petroni, R.K. Amaravadi, E.H. Baehrecke, A. Ballabio, P. Boya, J.M. Bravo-San Pedro, et al. 2021. Autophagy in major human diseases. EMBO Journal 40 (19): e108863. https://doi.org/10.15252/embj.2021108863.CrossRefPubMedPubMedCentral

131.

Parzych, K.R., and D.J. Klionsky. 2014. An overview of autophagy: Morphology, mechanism, and regulation. Antioxidants & Redox Signaling 20 (3): 460–473. https://doi.org/10.1089/ars.2013.5371.CrossRef

132.

Lechner, K., C. von Schacky, A.L. McKenzie, N. Worm, U. Nixdorff, B. Lechner, N. Krankel, M. Halle, R.M. Krauss, and J. Scherr. 2020. Lifestyle factors and high-risk atherosclerosis: Pathways and mechanisms beyond traditional risk factors. European Journal of Preventive Cardiology 27 (4): 394–406. https://doi.org/10.1177/2047487319869400.CrossRefPubMed

133.

Zhu, L., and L. Liu. 2022. New Insights Into the Interplay Among Autophagy, the NLRP3 Inflammasome and Inflammation in Adipose Tissue. Front Endocrinol (Lausanne) 13: 739882. https://doi.org/10.3389/fendo.2022.739882.CrossRefPubMed

134.

Razani, B., C. Feng, T. Coleman, R. Emanuel, H. Wen, S. Hwang, J.P. Ting, H.W. Virgin, M.B. Kastan, and C.F. Semenkovich. 2012. Autophagy links inflammasomes to atherosclerotic progression. Cell Metabolism 15 (4): 534–544. https://doi.org/10.1016/j.cmet.2012.02.011.CrossRefPubMedPubMedCentral

135.

Ma, S., J. Chen, J. Feng, R. Zhang, M. Fan, D. Han, X. Li, et al. 2018. Melatonin Ameliorates the Progression of Atherosclerosis via Mitophagy Activation and NLRP3 Inflammasome Inhibition. Oxidative Medicine and Cellular Longevity 2018: 9286458. https://doi.org/10.1155/2018/9286458.CrossRefPubMedPubMedCentral

136.

Shen, L., Y. Yang, T. Ou, C.C. Key, S.H. Tong, R.C. Sequeira, J.M. Nelson, et al. 2017. Dietary PUFAs attenuate NLRP3 inflammasome activation via enhancing macrophage autophagy. Journal of Lipid Research 58 (9): 1808–1821. https://doi.org/10.1194/jlr.M075879.CrossRefPubMedPubMedCentral

137.

Abderrazak, A., D. Couchie, D.F. Mahmood, R. Elhage, C. Vindis, M. Laffargue, V. Mateo, et al. 2015. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Circulation 131 (12):1061–1070. https://doi.org/10.1161/CIRCULATIONAHA.114.013730.

Titel: NLRP3 Inflammasome in Atherosclerosis: Putting Out the Fire of Inflammation
verfasst von: Bo-Zong Shao
Hai-Yan Xu
Yi-Cheng Zhao
Xiao-Rui Zheng
Fang Wang
Guan-Ren Zhao
Publikationsdatum: 11.08.2022
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 1/2023
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-022-01725-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

NLRP3 Inflammasome in Atherosclerosis: Putting Out the Fire of Inflammation

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways

Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics

Investigation of TLR4 Antagonists for Prevention of Intestinal Inflammation

The Influenza-Induced Pulmonary Inflammatory Exudate in Susceptible Tpl2-Deficient Mice Is Dictated by Type I IFN Signaling

Decreased Th1 Cells and Increased Th2 Cells in Peripheral Blood Are Associated with Idiopathic Inflammatory Myopathies Patients with Interstitial Lung Disease

Circ_0088194 Regulates Proliferation, Migration, Apoptosis, and Inflammation by miR-30a-3p/ADAM10 Axis in Rheumatoid Arthritis Fibroblastic Synovial Cells

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Update Innere Medizin